Department of Medicine/Nephrology, Hannover Medical School, Hannover, Germany.
Mount Desert Island Biological Laboratory, Salisbury Cove, Maine, USA.
Sci Rep. 2018 Feb 26;8(1):3621. doi: 10.1038/s41598-018-22070-w.
So far the pathomechanism of preeclampsia in pregnancy is focussed on increased circulating levels of soluble fms-like tyrosin kinase-1 (sFLT-1) that neutralizes glomerular VEGF-A expression and prevents its signaling at the glomerular endothelium. As a result of changed glomerular VEGF-A levels endotheliosis and podocyte foot process effacement are typical morphological features of preeclampsia. Recently, microRNA-26a-5p (miR-26a-5p) was described to be also upregulated in the preeclamptic placenta. We found that miR-26a-5p targets VEGF-A expression by means of PIK3C2α in cultured human podocytes and that miR-26a-5p overexpression in zebrafish causes proteinuria, edema, glomerular endotheliosis and podocyte foot process effacement. Interestingly, recombinant zebrafish Vegf-Aa protein could rescue glomerular changes induced by miR-26a-5p. In a small pilot study, preeclamptic patients with podocyte damage identified by podocyturia, expressed significantly more urinary miR-26a-5p compared to healthy controls. Thus, functional and ultrastructural glomerular changes after miR-26a-5p overexpression can resemble the findings seen in preeclampsia and indicate a potential pathophysiological role of miR-26a-5p in addition to sFLT-1 in this disease.
迄今为止,妊娠子痫前期的发病机制主要集中在循环中可溶性 fms 样酪氨酸激酶-1(sFLT-1)水平升高,其可中和肾小球血管内皮生长因子 A(VEGF-A)的表达并阻止其在肾小球内皮细胞的信号传递。由于肾小球 VEGF-A 水平的改变,内皮细胞病和足细胞足突消失是子痫前期的典型形态学特征。最近,microRNA-26a-5p(miR-26a-5p)也被描述为在子痫前期胎盘组织中上调。我们发现,miR-26a-5p 通过 PIK3C2α 靶向人足细胞中 VEGF-A 的表达,而在斑马鱼中过表达 miR-26a-5p 会导致蛋白尿、水肿、肾小球内皮细胞病和足细胞足突消失。有趣的是,重组斑马鱼 Vegf-Aa 蛋白可挽救 miR-26a-5p 引起的肾小球变化。在一项小型初步研究中,通过尿足细胞计数发现有足细胞损伤的子痫前期患者,其尿中 miR-26a-5p 的表达明显高于健康对照组。因此,miR-26a-5p 过表达后的功能和超微结构肾小球变化与子痫前期所见相似,表明 miR-26a-5p 在除 sFLT-1 之外,在该疾病中具有潜在的病理生理学作用。